The University of Chicago Header Logo

Connection

Wendy Stock to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Back to Details
This is a "connection" page, showing publications Wendy Stock has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Wendy Stock
Connection Strength
19.936
Precursor Cell Lymphoblastic Leukemia-Lymphoma
  1. Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study. Cancer. 2025 Feb 15; 131(4):e35750.
    View in: PubMed
    Score: 0.663
  2. Abatement of the Survival Cliff in Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in the United States. J Adolesc Young Adult Oncol. 2025 Feb; 14(1):33-42.
    View in: PubMed
    Score: 0.646
  3. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.628
  4. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
    View in: PubMed
    Score: 0.556
  5. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! JCO Oncol Pract. 2022 07; 18(7):479-487.
    View in: PubMed
    Score: 0.544
  6. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 06; 11(6):1440-1453.
    View in: PubMed
    Score: 0.503
  7. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
    View in: PubMed
    Score: 0.501
  8. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.
    View in: PubMed
    Score: 0.495
  9. Thrombosis in ALL: a risk without clear mitigation. Blood. 2020 07 16; 136(3):264-265.
    View in: PubMed
    Score: 0.483
  10. Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncol Pract. 2020 05; 16(5):231-238.
    View in: PubMed
    Score: 0.468
  11. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. Blood. 2019 04 18; 133(16):1715-1719.
    View in: PubMed
    Score: 0.438
  12. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
    View in: PubMed
    Score: 0.435
  13. Should immunologic strategies be incorporated into frontline ALL therapy? Best Pract Res Clin Haematol. 2018 12; 31(4):367-372.
    View in: PubMed
    Score: 0.426
  14. Management of acute lymphoblastic leukemia in young adults. Clin Adv Hematol Oncol. 2018 Feb; 16(2):138-146.
    View in: PubMed
    Score: 0.407
  15. Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):28-36.
    View in: PubMed
    Score: 0.403
  16. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.
    View in: PubMed
    Score: 0.375
  17. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279.
    View in: PubMed
    Score: 0.358
  18. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
    View in: PubMed
    Score: 0.356
  19. Novel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5.
    View in: PubMed
    Score: 0.342
  20. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015 Jun 11; 125(24):3702-10.
    View in: PubMed
    Score: 0.334
  21. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.276
  22. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
    View in: PubMed
    Score: 0.260
  23. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2010 Feb; 51(2):188-98.
    View in: PubMed
    Score: 0.234
  24. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:21-9.
    View in: PubMed
    Score: 0.233
  25. Preface: acute lymphoblastic leukemia--quo vadis? Hematol Oncol Clin North Am. 2009 Oct; 23(5):xi-xviii.
    View in: PubMed
    Score: 0.229
  26. Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1099-119, vii.
    View in: PubMed
    Score: 0.229
  27. Pediatric regimens for adult acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009 Apr; 7(4):244-6.
    View in: PubMed
    Score: 0.221
  28. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol. 2008 Jul; 15(4):400-7.
    View in: PubMed
    Score: 0.210
  29. Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2008 Jul; 6(7):487-8.
    View in: PubMed
    Score: 0.210
  30. Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):144-51.
    View in: PubMed
    Score: 0.210
  31. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54.
    View in: PubMed
    Score: 0.208
  32. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
    View in: PubMed
    Score: 0.172
  33. Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. JNCI Cancer Spectr. 2025 Apr 30; 9(3).
    View in: PubMed
    Score: 0.168
  34. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar 25; 9(6):1442-1451.
    View in: PubMed
    Score: 0.167
  35. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025 02 06; 145(6):577-589.
    View in: PubMed
    Score: 0.166
  36. Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2025 May 01; 110(5):1105-1114.
    View in: PubMed
    Score: 0.163
  37. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 06 25; 8(12):3226-3236.
    View in: PubMed
    Score: 0.159
  38. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681.
    View in: PubMed
    Score: 0.157
  39. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.154
  40. Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL. Leukemia. 2024 03; 38(3):491-501.
    View in: PubMed
    Score: 0.153
  41. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.153
  42. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.
    View in: PubMed
    Score: 0.151
  43. Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.
    View in: PubMed
    Score: 0.144
  44. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204.
    View in: PubMed
    Score: 0.144
  45. Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding. Expert Opin Drug Metab Toxicol. 2023 Jan-Jun; 19(6):357-366.
    View in: PubMed
    Score: 0.143
  46. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022 12 01; 107(12):2783-2793.
    View in: PubMed
    Score: 0.142
  47. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
    View in: PubMed
    Score: 0.141
  48. D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022 09 13; 6(17):5146-5151.
    View in: PubMed
    Score: 0.140
  49. Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. J Assist Reprod Genet. 2022 Aug; 39(8):1733-1738.
    View in: PubMed
    Score: 0.138
  50. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022 06 16; 139(24):3519-3531.
    View in: PubMed
    Score: 0.138
  51. Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Adv. 2022 06 14; 6(11):3386-3397.
    View in: PubMed
    Score: 0.138
  52. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022 06; 3(6):768-782.
    View in: PubMed
    Score: 0.137
  53. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022 Jun; 150:113000.
    View in: PubMed
    Score: 0.137
  54. MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444.
    View in: PubMed
    Score: 0.135
  55. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.
    View in: PubMed
    Score: 0.135
  56. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700.
    View in: PubMed
    Score: 0.133
  57. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022 05; 53:100908.
    View in: PubMed
    Score: 0.132
  58. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):725-733.
    View in: PubMed
    Score: 0.129
  59. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.
    View in: PubMed
    Score: 0.127
  60. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
    View in: PubMed
    Score: 0.126
  61. Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol. 2001 Jan; 13(1):14-20.
    View in: PubMed
    Score: 0.125
  62. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix.
    View in: PubMed
    Score: 0.124
  63. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
    View in: PubMed
    Score: 0.124
  64. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020 10 10; 10:CD013399.
    View in: PubMed
    Score: 0.123
  65. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.
    View in: PubMed
    Score: 0.121
  66. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.
    View in: PubMed
    Score: 0.121
  67. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 08; 95:106385.
    View in: PubMed
    Score: 0.120
  68. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015.
    View in: PubMed
    Score: 0.119
  69. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71.
    View in: PubMed
    Score: 0.118
  70. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 03; 1(3):329-344.
    View in: PubMed
    Score: 0.118
  71. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457.
    View in: PubMed
    Score: 0.117
  72. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
    View in: PubMed
    Score: 0.116
  73. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
    View in: PubMed
    Score: 0.115
  74. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020 03; 61(3):614-622.
    View in: PubMed
    Score: 0.115
  75. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123.
    View in: PubMed
    Score: 0.113
  76. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729.
    View in: PubMed
    Score: 0.111
  77. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416.
    View in: PubMed
    Score: 0.109
  78. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol. 2018 10; 93(10):1254-1266.
    View in: PubMed
    Score: 0.106
  79. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 05 01; 4(5):725-734.
    View in: PubMed
    Score: 0.104
  80. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
    View in: PubMed
    Score: 0.102
  81. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
    View in: PubMed
    Score: 0.101
  82. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018 Jun; 24(4):299-308.
    View in: PubMed
    Score: 0.096
  83. Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):312-320.
    View in: PubMed
    Score: 0.095
  84. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958.
    View in: PubMed
    Score: 0.094
  85. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331.
    View in: PubMed
    Score: 0.093
  86. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016 12; 48(12):1481-1489.
    View in: PubMed
    Score: 0.093
  87. Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer. 2017 Jan 01; 123(1):122-130.
    View in: PubMed
    Score: 0.093
  88. The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What? Biol Blood Marrow Transplant. 2016 11; 22(11):1913-1914.
    View in: PubMed
    Score: 0.092
  89. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
    View in: PubMed
    Score: 0.091
  90. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res. 2015 Dec; 39(12):1437-42.
    View in: PubMed
    Score: 0.087
  91. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6.
    View in: PubMed
    Score: 0.082
  92. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.
    View in: PubMed
    Score: 0.081
  93. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan; 99(1):111-5.
    View in: PubMed
    Score: 0.075
  94. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013 Mar; 45(3):242-52.
    View in: PubMed
    Score: 0.072
  95. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83.
    View in: PubMed
    Score: 0.071
  96. Children, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012 Nov 10; 30(32):4037-8; author reply 4038-9.
    View in: PubMed
    Score: 0.070
  97. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010 Mar 01; 116(5):1165-76.
    View in: PubMed
    Score: 0.059
  98. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63.
    View in: PubMed
    Score: 0.058
  99. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 Dec 01; 115(23):5490-8.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.